{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T01:09:00Z","timestamp":1783386540967,"version":"3.54.6"},"reference-count":194,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.bcp.2017.03.019","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T06:09:11Z","timestamp":1490940551000},"page":"56-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"special_numbering":"C","title":["Cancer combination therapies with artemisinin-type drugs"],"prefix":"10.1016","volume":"139","author":[{"given":"Thomas","family":"Efferth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.bcp.2017.03.019_b0005","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.phymed.2015.10.003","article-title":"Nobel Prize for artemisinin brings phytotherapy into the spotlight","volume":"22","author":"Efferth","year":"2015","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bcp.2017.03.019_b0010","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1475-2875-10-84","article-title":"Evaluation and pharmacovigilance of projects promoting cultivation and local use of Artemisia annua for malaria","volume":"10","author":"Willcox","year":"2011","journal-title":"Malar. J."},{"issue":"4","key":"10.1016\/j.bcp.2017.03.019_b0015","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5497\/wjp.v3.i4.39","article-title":"Dried-leaf Artemisia annua: a practical malaria therapeutic for developing countries?","volume":"3","author":"Weathers","year":"2014","journal-title":"World J. Pharmacol."},{"key":"10.1016\/j.bcp.2017.03.019_b0020","first-page":"196","article-title":"Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs","volume":"46","author":"Efferth","year":"1996","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.bcp.2017.03.019_b0025","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1086\/591195","article-title":"The antiviral activities of artemisinin and artesunate","volume":"47","author":"Efferth","year":"2008","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.bcp.2017.03.019_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15806\/j.issn.2311-8571.2016.0002","article-title":"Expanding the therapeutic spectrum of artemisinin: activity against infectious diseases beyond malaria and novel pharmaceutical developments","volume":"2","author":"Efferth","year":"2016","journal-title":"World J. Trad. Chin. Med."},{"key":"10.1016\/j.bcp.2017.03.019_b0035","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.pharmthera.2013.12.001","article-title":"Artemisinins: pharmacological actions beyond anti-malarial","volume":"142","author":"Ho","year":"2014","journal-title":"Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2017.03.019_b0040","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.phymed.2015.01.012","article-title":"Cytotoxicity of natural products and derivatives toward MCF-7 cell monolayers and cancer stem-like mammospheres","volume":"22","author":"Seo","year":"2015","journal-title":"Phytomedicine"},{"issue":"11","key":"10.1016\/j.bcp.2017.03.019_b0045","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.phymed.2015.08.002","article-title":"Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells","volume":"22","author":"Ooko","year":"2015","journal-title":"Phytomedicine"},{"issue":"11","key":"10.1016\/j.bcp.2017.03.019_b0050","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.phymed.2016.06.004","article-title":"Artesunate attenuated progression of atherosclerosis lesion formation alone or combined with rosuvastatin through inhibition of pro-inflammatory cytokines and pro-inflammatory chemokines","volume":"23","author":"Jiang","year":"2016","journal-title":"Phytomedicine"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2017.03.019_b0055","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.cell.2016.11.010","article-title":"Artemisinins target GABAA receptor signaling and impair \u03b1 cell identity","volume":"168","author":"Li","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2017.03.019_b0060","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.phrs.2016.02.017","article-title":"Antischistosomal activity of artemisinin derivatives in vivo and in patients","volume":"110","author":"Saeed","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.bcp.2017.03.019_b0065","first-page":"1599","article-title":"Artesunate in the treatment of metastatic uveal melanoma\u2013first experiences","volume":"14","author":"Berger","year":"2005","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2017.03.019_b0070","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3736\/jcim20080206","article-title":"Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled trial","volume":"6","author":"Zhang","year":"2008","journal-title":"Zhong Xi Yi Jie He Xue Bao"},{"issue":"14","key":"10.1016\/j.bcp.2017.03.019_b0075","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.phymed.2015.11.001","article-title":"Activity of artemisia annua and artemisinin derivatives, in prostate carcinoma","volume":"22","author":"Michaelsen","year":"2015","journal-title":"Phytomedicine"},{"issue":"3","key":"10.1016\/j.bcp.2017.03.019_b0080","first-page":"46","article-title":"Principles of current cancer chemotherapy","volume":"9","author":"Wiemann","year":"1983","journal-title":"Compr. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2017.03.019_b0085","first-page":"249","article-title":"Principles of adjuvant therapy","volume":"54","author":"Dawson","year":"1995","journal-title":"Br. J. Hosp. Med."},{"issue":"5\u20136","key":"10.1016\/j.bcp.2017.03.019_b0090","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.drup.2012.10.003","article-title":"Understanding resistance to combination chemotherapy","volume":"15","author":"Pritchard","year":"2012","journal-title":"Drug Resist. Updat."},{"issue":"1","key":"10.1016\/j.bcp.2017.03.019_b0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.synres.2014.07.003","article-title":"Frequently asked questions in drug combinations and the mass-action law-based answers","volume":"1","author":"Chou","year":"2014","journal-title":"Synergy"},{"issue":"3","key":"10.1016\/j.bcp.2017.03.019_b0100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.synres.2016.06.001","article-title":"Drug combination in vivo using combination index method: Taxotere and T607 against colon carcinoma HCT-116 xenograft tumor in nude mice","volume":"3","author":"Fu","year":"2016","journal-title":"Synergy"},{"issue":"5","key":"10.1016\/j.bcp.2017.03.019_b0105","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.phymed.2015.03.001","article-title":"Marsdenia tenacissima extract enhances gefitinib efficacy in non-small cell lung cancer xenografts","volume":"22","author":"Han","year":"2015","journal-title":"Phytomedicine"},{"issue":"13","key":"10.1016\/j.bcp.2017.03.019_b0110","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.phymed.2016.09.003","article-title":"Immunomodulatory proteins FIP-gts and chloroquine induce caspase-independent cell death via autophagy for resensitizing cisplatin-resistant urothelial cancer cells","volume":"23","author":"Hsin","year":"2016","journal-title":"Phytomedicine"},{"issue":"3","key":"10.1016\/j.bcp.2017.03.019_b0115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.phymed.2015.12.020","article-title":"Resveratrol improves the anticancer effects of doxorubicin in vitro and in vivo models: A mechanistic insight","volume":"23","author":"Rai","year":"2016","journal-title":"Phytomedicine"},{"issue":"13","key":"10.1016\/j.bcp.2017.03.019_b0120","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.phymed.2016.09.008","article-title":"Sageone, a diterpene from Rosmarinus officinalis, synergizes with cisplatin cytotoxicity in SNU-1 human gastric cancer cells","volume":"23","author":"Shrestha","year":"2016","journal-title":"Phytomedicine"},{"issue":"14","key":"10.1016\/j.bcp.2017.03.019_b0125","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.phymed.2016.10.018","article-title":"Combination of baicalein and 10-hydroxy camptothecin exerts remarkable synergetic anti-cancer effects","volume":"23","author":"Tang","year":"2016","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1016\/j.bcp.2017.03.019_b0130","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2174\/138945011793591626","article-title":"Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy","volume":"12","author":"Efferth","year":"2011","journal-title":"Curr. Drug Targets"},{"issue":"2","key":"10.1016\/j.bcp.2017.03.019_b0135","first-page":"165","article-title":"Impact of viral oncogenesis on responses to anti-cancer drugs and irradiation","volume":"11","author":"Efferth","year":"2000","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.bcp.2017.03.019_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2017.02.009","article-title":"From ancient herb to modern drug: artemisia annua and artemisinin for cancer therapy","author":"Efferth","year":"2017","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2017.03.019_b0145","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1124\/mol.64.2.382","article-title":"Molecular modes of action of artesunate in tumor cell lines","volume":"64","author":"Efferth","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2017.03.019_b0150","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1158\/0008-5472.CAN-07-2970","article-title":"Artesunate derived from traditional Chinese medicine induces DNA damage and repair","volume":"68","author":"Li","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2017.03.019_b0155","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1158\/1535-7163.MCT-11-0534","article-title":"Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM\/ATR damage response in cancer cells","volume":"10","author":"Berdelle","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2017.03.019_b0160","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/jat.1734","article-title":"In vitro evaluation of the cytotoxic and genotoxic effects of artemether, an antimalarial drug, in a gastric cancer cell line (PG100)","volume":"33","author":"Alcantara","year":"2013","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.bcp.2017.03.019_b0165","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.4238\/2013.July.24.6","article-title":"Genotoxic evaluation of the antimalarial drugs artemisinin and artesunate in human HepG2 cells and effects on CASP3 and SOD1 gene expressions","volume":"12","author":"Aquino","year":"2013","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.bcp.2017.03.019_b0170","first-page":"1339","article-title":"DNA damage in dihydroartemisinin-resistant Molt-4 cells","volume":"35","author":"Park","year":"2015","journal-title":"Anticancer Res."},{"issue":"10","key":"10.1016\/j.bcp.2017.03.019_b0175","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1080\/15384047.2015.1071738","article-title":"Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51","volume":"16","author":"Wang","year":"2015","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2017.03.019_b0180","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/1566524013364194","article-title":"The human ATP-binding cassette transporter genes: from the bench to the bedside","volume":"1","author":"Efferth","year":"2001","journal-title":"Curr. Mol. Med."},{"issue":"2","key":"10.1016\/j.bcp.2017.03.019_b0185","first-page":"237","article-title":"Chemotherapy-induced resistance by ATP-binding cassette transporter genes","volume":"1775","author":"Gillet","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"7","key":"10.1016\/j.bcp.2017.03.019_b0190","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/bjc.1997.164","article-title":"Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage","volume":"75","author":"Kinsella","year":"1997","journal-title":"Br. J. Cancer"},{"issue":"47","key":"10.1016\/j.bcp.2017.03.019_b0195","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1038\/sj.onc.1206946","article-title":"Resistance to antifolates","volume":"22","author":"Zhao","year":"2003","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.bcp.2017.03.019_b0200","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.bbapap.2012.12.009","article-title":"Mechanisms of resistance to BCR-ABL and other kinase inhibitors","volume":"1834","author":"Lamontanara","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcp.2017.03.019_b0205","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.phrs.2016.01.001","article-title":"Cisplatin resistance and opportunities for precision medicine","volume":"106","author":"Amable","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2017.03.019_b0210","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.drup.2012.03.002","article-title":"Collateral sensitivity as a strategy against cancer multidrug resistance","volume":"15","author":"Pluchino","year":"2012","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bcp.2017.03.019_b0215","series-title":"Tumor Cell Resistance to Apoptosis by Cytotoxic Drugs and Reversal of Resistance by Targeted Sensitizing Cells","first-page":"187","article-title":"Collateral sensitivity in drug-resistant tumor cells","author":"Saeed","year":"2013"},{"issue":"4","key":"10.1016\/j.bcp.2017.03.019_b0220","doi-asserted-by":"crossref","first-page":"2","DOI":"10.15806\/j.issn.2311-8571.2015.0036","article-title":"Artemisinin \u2013 second career as anticancer drug?","volume":"1","author":"Efferth","year":"2015","journal-title":"World J. Trad. Chin. Med."},{"issue":"5","key":"10.1016\/j.bcp.2017.03.019_b0225","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1582-4934.2010.01120.x","article-title":"Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties","volume":"15","author":"Soomro","year":"2011","journal-title":"J. Cell Mol. Med."},{"issue":"5","key":"10.1016\/j.bcp.2017.03.019_b0230","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.cllc.2014.05.005","article-title":"Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non-small-cell lung cancer: a propensity score matching analysis","volume":"15","author":"Kim","year":"2014","journal-title":"Clin. Lung Cancer"},{"issue":"12","key":"10.1016\/j.bcp.2017.03.019_b0235","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1001\/jamaoto.2016.1876","article-title":"Modern image-guided intensity-modulated radiotherapy for oropharynx cancer and severe late toxic effects: implications for clinical trial design","volume":"142","author":"Ward","year":"2016","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"issue":"11","key":"10.1016\/j.bcp.2017.03.019_b0240","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13014-016-0670-2","article-title":"Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer","volume":"26","author":"White","year":"2016","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.bcp.2017.03.019_b0245","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.semcancer.2015.09.009","article-title":"Radiation resistance: Cancer stem cells (CSCs) and their enigmatic pro-survival signaling","volume":"35","author":"Skvortsova","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2017.03.019_b0250","first-page":"6146595","article-title":"Role of natural radiosensitizers and cancer cell radioresistance: an update","volume":"2016","author":"Malik","year":"2016","journal-title":"Anal. Cell Pathol. (Amst.)"},{"issue":"2","key":"10.1016\/j.bcp.2017.03.019_b0255","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00432-005-0052-x","article-title":"Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro","volume":"132","author":"Kim","year":"2006","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bcp.2017.03.019_b0260","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.intimp.2011.08.017","article-title":"Artesunate enhances radiosensitivity of human non-small cell lung cancer A549 cells via increasing NO production to induce cell cycle arrest at G2\/M phase","volume":"11","author":"Zhao","year":"2011","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2017.03.019_b0265","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.radonc.2012.03.018","article-title":"A radiosensitizing effect of artesunate in glioblastoma cells is associated with a diminished expression of the inhibitor of apoptosis protein survivin","volume":"103","author":"Reichert","year":"2012","journal-title":"Radiother. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2017.03.019_b0270","first-page":"254","article-title":"Dihydroartemisinin induces radiosensitivity in cervical cancer cells by modulating cell cycle progression","volume":"34","author":"Luo","year":"2013","journal-title":"Saudi Med. J."},{"issue":"10","key":"10.1016\/j.bcp.2017.03.019_b0275","first-page":"1220","article-title":"Effect of dihydroartemisinin combined irradiation on the apoptosis of human lung cancer GLC-82 cells and its mechanism study","volume":"34","author":"Zuo","year":"2014","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi"},{"key":"10.1016\/j.bcp.2017.03.019_b0280","doi-asserted-by":"crossref","DOI":"10.1002\/tcr.201600121","article-title":"Photodynamic therapy: past, present and future","author":"Chilakamarthi","year":"2017","journal-title":"Chem. Rec."},{"issue":"5","key":"10.1016\/j.bcp.2017.03.019_b0285","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1159\/000358716","article-title":"Dihydroartemisinin accentuates the anti-tumor effects of photodynamic therapy via inactivation of NF-\u03baB in Eca109 and Ec9706 esophageal cancer cells","volume":"33","author":"Li","year":"2014","journal-title":"Cell. Physiol. Biochem."},{"issue":"7\u20138","key":"10.1016\/j.bcp.2017.03.019_b0290","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1345\/aph.1R769","article-title":"Drug interactions and the pharmacist: focus on everolimus","volume":"47","author":"Grabowsky","year":"2013","journal-title":"Ann. Pharmacother."},{"issue":"11","key":"10.1016\/j.bcp.2017.03.019_b0295","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.bcp.2017.03.019_b0300","first-page":"281","article-title":"Captopril augments antitumor activity of cyclophosphamide in mice","volume":"48","author":"Kowalski","year":"1996","journal-title":"Pol. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2017.03.019_b0305","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00432-009-0587-3","article-title":"Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy","volume":"135","author":"Wilop","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bcp.2017.03.019_b0310","doi-asserted-by":"crossref","first-page":"454783","DOI":"10.1155\/2013\/454783","article-title":"Synergistic inhibition of angiogenesis by artesunate and captopril in vitro and in vivo","volume":"2013","author":"Krusche","year":"2013","journal-title":"Evid. Based Complement. Alternat. Med."},{"issue":"17","key":"10.1016\/j.bcp.2017.03.019_b0315","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/jnci\/djn262","article-title":"Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial","volume":"100","author":"Christian","year":"2008","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.bcp.2017.03.019_b0320","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejphar.2015.12.017","article-title":"Time to use a dose of chloroquine as an adjuvant to anti-cancer chemotherapies","volume":"771","author":"Pascolo","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2017.03.019_b0325","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.biochi.2014.10.001","article-title":"Inhibition of autophagy by chloroquine potentiates synergistically anti-cancer property of artemisinin by promoting ROS dependent apoptosis","volume":"107 Pt B","author":"Ganguli","year":"2014","journal-title":"Biochimie"},{"issue":"9","key":"10.1016\/j.bcp.2017.03.019_b0330","first-page":"CD000026","article-title":"Routine versus selective antifungal administration for control of fungal infections in patients with cancer","author":"G\u00f8tzsche","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.bcp.2017.03.019_b0335","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.4103\/0973-1482.137975","article-title":"A survey on anticancer effects of artemisinin, iron, miconazole, and butyric acid on 5637 (bladder cancer) and 4T1 (Breast cancer) cell lines","volume":"10","author":"Shahbazfar","year":"2014","journal-title":"J. Cancer Res. Ther."},{"issue":"1\u20133","key":"10.1016\/j.bcp.2017.03.019_b0340","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF00744663","article-title":"Glutathione-related enzymes, glutathione and multidrug resistance","volume":"12","author":"Moscow","year":"1993","journal-title":"Cytotechnology"},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2017.03.019_b0345","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/0169-5002(94)91668-3","article-title":"Fundamental bases of combined therapy in lung cancer: cell resistance to chemotherapy and radiotherapy","volume":"10","author":"Duchesne","year":"1994","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2017.03.019_b0350","first-page":"225","article-title":"Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate","volume":"19","author":"Efferth","year":"2005","journal-title":"In Vivo"},{"issue":"2","key":"10.1016\/j.bcp.2017.03.019_b0355","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2174\/18715206113136660337","article-title":"Glucose-6-phosphate dehydrogenase: a biomarker and potential therapeutic target for cancer","volume":"14","author":"Zhang","year":"2014","journal-title":"Anticancer Agents Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2017.03.019_b0360","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.3892\/mmr.2015.3995","article-title":"Zoledronic acid inhibits the pentose phosphate pathway through attenuating the Ras-TAp73-G6PD axis in bladder cancer cells","volume":"12","author":"Wang","year":"2015","journal-title":"Mol. Med. Rep."},{"issue":"6","key":"10.1016\/j.bcp.2017.03.019_b0365","doi-asserted-by":"crossref","first-page":"32734","DOI":"10.1038\/srep32734","article-title":"SIRT2 activates G6PD to enhance NADPH production and promote leukaemia cell proliferation","volume":"2","author":"Xu","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2017.03.019_b0370","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1042\/BJ20102016","article-title":"Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity","volume":"439","author":"Polimeni","year":"2011","journal-title":"Biochem J."},{"issue":"1","key":"10.1016\/j.bcp.2017.03.019_b0375","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF00203619","article-title":"Increased induction of apoptosis in mononuclear cells of a glucose-6-phosphate dehydrogenase deficient patient","volume":"73","author":"Efferth","year":"1995","journal-title":"J. Mol. Med. (Berl)"},{"issue":"3","key":"10.1016\/j.bcp.2017.03.019_b0380","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1189\/jlb.69.3.340","article-title":"DNA damage and apoptosis in mononuclear cells from glucose-6-phosphate dehydrogenase-deficient patients (G6PD Aachen variant) after UV irradiation","volume":"69","author":"Efferth","year":"2001","journal-title":"J. Leukoc. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2017.03.019_b0385","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/sj.cdd.4401807","article-title":"Role of glucose-6-phosphate dehydrogenase for oxidative stress and apoptosis","volume":"13","author":"Efferth","year":"2006","journal-title":"Cell Death Differ."},{"issue":"2","key":"10.1016\/j.bcp.2017.03.019_b0390","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/onc.2016.196","article-title":"Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin","volume":"36","author":"Elf","year":"2017","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.bcp.2017.03.019_b0395","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/jcb.24684","article-title":"ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation","volume":"115","author":"Qie","year":"2014","journal-title":"J. Cell. Biochem."},{"issue":"6","key":"10.1016\/j.bcp.2017.03.019_b0400","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.3892\/mmr.2015.3261","article-title":"Silencing of glutaminase 1 resensitizes Taxol-resistant breast cancer cells to Taxol","volume":"11","author":"Fu","year":"2015","journal-title":"Mol. Med. Rep."},{"issue":"10","key":"10.1016\/j.bcp.2017.03.019_b0405","first-page":"4265","article-title":"Glutaminase inhibitor compound 968 inhibits cell proliferation and sensitizes paclitaxel in ovarian cancer","volume":"8","author":"Yuan","year":"2016","journal-title":"Am. J. Transl. Res."},{"issue":"11","key":"10.1016\/j.bcp.2017.03.019_b0410","doi-asserted-by":"crossref","first-page":"e0166423","DOI":"10.1371\/journal.pone.0166423","article-title":"The Glutaminase-1 inhibitor 968 enhances dihydroartemisinin-mediated antitumor efficacy in hepatocellular carcinoma cells","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2017.03.019_b0415","article-title":"Selective histone deacetylase small molecule inhibitors: recent progress and perspectives","author":"Qin","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bcp.2017.03.019_b0420","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/bs.acr.2016.01.007","article-title":"Inhibitors of DNA methylation, histone deacetylation, and histone demethylation: a perfect combination for cancer therapy","volume":"130","author":"Zahnow","year":"2016","journal-title":"Adv. Cancer Res."},{"issue":"1\u20133","key":"10.1016\/j.bcp.2017.03.019_b0425","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejphar.2009.10.033","article-title":"MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells","volume":"627","author":"Flis","year":"2010","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2017.03.019_b0430","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1007\/s10637-010-9467-6","article-title":"The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines","volume":"29","author":"Budman","year":"2011","journal-title":"Invest. New Drugs"},{"issue":"11\u201312","key":"10.1016\/j.bcp.2017.03.019_b0435","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/prca.201400058","article-title":"Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells","volume":"8","author":"Colarossi","year":"2014","journal-title":"Proteom. Clin. Appl."},{"issue":"6","key":"10.1016\/j.bcp.2017.03.019_b0440","doi-asserted-by":"crossref","first-page":"e39870","DOI":"10.1371\/journal.pone.0039870","article-title":"Histone deacetylase inhibitors facilitate dihydroartemisinin-induced apoptosis in liver cancer in vitro and in vivo","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.bcp.2017.03.019_b0445","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2174\/187152011795677517","article-title":"Anti-cancer activity of nitrones and observations on mechanism of action","volume":"11","author":"Floyd","year":"2011","journal-title":"Anticancer Agents Med. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2017.03.019_b0450","first-page":"4389","article-title":"Cytotoxicity of dihydroartemisinin toward Molt-4 cells attenuated by N-tert-butyl-alpha-phenylnitrone and deferoxamine","volume":"33","author":"Chan","year":"2013","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2017.03.019_b0455","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1021\/np200906s","article-title":"Natural products as sources of new drugs over the 30 years from 1981 to 2010","volume":"75","author":"Newman","year":"2012","journal-title":"J. Nat. Prod."},{"issue":"3","key":"10.1016\/j.bcp.2017.03.019_b0460","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1021\/acs.jnatprod.5b01055","article-title":"Natural products as sources of new drugs from 1981 to 2014","volume":"79","author":"Newman","year":"2016","journal-title":"J. Nat. Prod."},{"issue":"5","key":"10.1016\/j.bcp.2017.03.019_b0465","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.3390\/molecules15053135","article-title":"Flavonoids from Artemisia annua L. as antioxidants and their potential synergism with artemisinin against malaria and cancer","volume":"15","author":"Ferreira","year":"2010","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.bcp.2017.03.019_b0470","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.phymed.2011.06.008","article-title":"Cytotoxic activity of secondary metabolites derived from Artemisia annua L. towards cancer cells in comparison to its designated active constituent artemisinin","volume":"18","author":"Efferth","year":"2011","journal-title":"Phytomedicine"},{"issue":"7","key":"10.1016\/j.bcp.2017.03.019_b0475","doi-asserted-by":"crossref","first-page":"674","DOI":"10.2174\/1389450115666140526154642","article-title":"The synergistic effect of humanized monoclonal antibodies targeting insulin-like growth factor 1 receptor (IGF-1R) and chemotherapy","volume":"15","author":"Sui","year":"2014","journal-title":"Curr. Drug Targets"},{"issue":"34","key":"10.1016\/j.bcp.2017.03.019_b0480","doi-asserted-by":"crossref","first-page":"e1400","DOI":"10.1097\/MD.0000000000001400","article-title":"The efficacy of combining EGFR monoclonal antibody with chemotherapy for patients with advanced nonsmall cell lung cancer: a meta-analysis from 9 randomized controlled trials","volume":"94","author":"Sheng","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcp.2017.03.019_b0485","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.addr.2015.10.021","article-title":"Co-delivery of chemotherapeutics and proteins for synergistic therapy","volume":"98","author":"He","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.bcp.2017.03.019_b0490","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00262-008-0598-y","article-title":"Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer","volume":"58","author":"Zhang","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bcp.2017.03.019_b0495","article-title":"Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy","author":"Michelle","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2017.03.019_b0500","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/978-3-319-13150-4_11","article-title":"Management of diffuse large B-cell lymphoma (DLBCL)","volume":"165","author":"Kubuschok","year":"2015","journal-title":"Cancer Treat. Res."},{"issue":"25","key":"10.1016\/j.bcp.2017.03.019_b0505","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1038\/sj.onc.1210365","article-title":"Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo\/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions","volume":"26","author":"Bonavida","year":"2007","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.bcp.2017.03.019_b0510","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.seminoncol.2014.08.006","article-title":"Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance","volume":"41","author":"Bonavida","year":"2014","journal-title":"Semin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2017.03.019_b0515","first-page":"149","article-title":"Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate","volume":"35","author":"Sieber","year":"2009","journal-title":"Int. J. Oncol."},{"issue":"35 Suppl","key":"10.1016\/j.bcp.2017.03.019_b0520","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.semcancer.2015.03.001","article-title":"Broad targeting of resistance to apoptosis in cancer","author":"Mohammad","year":"2015","journal-title":"Semin. Cancer Biol."},{"issue":"5","key":"10.1016\/j.bcp.2017.03.019_b0525","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/cdd.2015.174","article-title":"Onto better TRAILs for cancer treatment","volume":"23","author":"de Miguel","year":"2016","journal-title":"Cell Death Differ."},{"issue":"9","key":"10.1016\/j.bcp.2017.03.019_b0530","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1517\/14728222.2015.1049838","article-title":"Targeting TRAIL in the treatment of cancer: new developments","volume":"19","author":"Lim","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"issue":"2","key":"10.1016\/j.bcp.2017.03.019_b0535","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1248\/cpb.c15-00732","article-title":"Bio-active natural products with TRAIL-resistance overcoming activity","volume":"64","author":"Ahmed","year":"2016","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"issue":"10","key":"10.1016\/j.bcp.2017.03.019_b0540","doi-asserted-by":"crossref","first-page":"819","DOI":"10.4161\/cbt.9.10.11552","article-title":"Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells","volume":"9","author":"He","year":"2010","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2017.03.019_b0545","first-page":"279","article-title":"Artesunate enhances TRAIL-induced apoptosis in human cervical carcinoma cells through inhibition of the NF-\u03baB and PI3K\/Akt signaling pathways","volume":"39","author":"Thanaketpaisarn","year":"2011","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bcp.2017.03.019_b0550","doi-asserted-by":"crossref","first-page":"e37222","DOI":"10.1371\/journal.pone.0037222","article-title":"Dihydroartemisinin enhances Apo2L\/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5","volume":"7","author":"Kong","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.bcp.2017.03.019_b0555","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.2174\/092986712800099820","article-title":"How is gene transfection able to improve current chemotherapy? The role of combined therapy in cancer treatment","volume":"19","author":"Prados","year":"2012","journal-title":"Curr. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2017.03.019_b0560","doi-asserted-by":"crossref","first-page":"e60834","DOI":"10.1371\/journal.pone.0060834","article-title":"Artemether combined with shRNA interference of vascular cell adhesion molecule-1 significantly inhibited the malignant biological behavior of human glioma cells","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.bcp.2017.03.019_b0565","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1002\/jcb.23114","article-title":"Down-regulation of BMI-1 cooperates with artemisinin on growth inhibition of nasopharyngeal carcinoma cells","volume":"112","author":"Wu","year":"2011","journal-title":"J. Cell. Biochem."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2017.03.019_b0570","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11010-013-1639-1","article-title":"Small interfering RNA targeting Rac1 sensitizes colon cancer to dihydroartemisinin-induced cell cycle arrest and inhibited cell migration by suppressing NF\u03baB activity","volume":"379","author":"Han","year":"2013","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bcp.2017.03.019_b0575","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.freeradbiomed.2014.03.026","article-title":"DJ-1 mediates the resistance of cancer cells to dihydroartemisinin through reactive oxygen species removal","volume":"71","author":"Zhu","year":"2014","journal-title":"Free Radic. Biol. Med."},{"issue":"5","key":"10.1016\/j.bcp.2017.03.019_b0580","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1080\/15384047.2015.1026477","article-title":"P8 attenuates the apoptosis induced by dihydroartemisinin in cancer cells through promoting autophagy","volume":"16","author":"Chen","year":"2015","journal-title":"Cancer Biol. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2017.03.019_b0585","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4155\/tde-2015-0003","article-title":"Nanocarrier-based co-delivery of small molecules and siRNA\/miRNA for treatment of cancer","volume":"7","author":"Chitkara","year":"2016","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.bcp.2017.03.019_b0590","article-title":"Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature","author":"Efferth","year":"2016","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.bcp.2017.03.019_b0595","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/10408441003610571","article-title":"Toxicity of the antimalarial artemisinin and its derivatives","volume":"40","author":"Efferth","year":"2010","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1016\/j.bcp.2017.03.019_b0600","first-page":"50","article-title":"Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials","volume":"58","author":"Ribeiro","year":"1998","journal-title":"Med. Trop."},{"key":"10.1016\/j.bcp.2017.03.019_b0605","first-page":"249","article-title":"Temozolomide induced liver injury","volume":"111","author":"Dixit","year":"2011","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.bcp.2017.03.019_b0610","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fonc.2016.00204","article-title":"Fatal liver and bone marrow toxicity by combination treatment of dichloroacetate and artesunate in a glioblastoma multiforme patient: case report and review of the literature","volume":"6","author":"Uhl","year":"2016","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2017.03.019_b0615","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00280-016-3038-2","article-title":"Evaluation of artemisinins for the treatment of acute myeloid leukemia","volume":"77","author":"Drenberg","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2017.03.019_b0620","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/08998280.2000.11927719","article-title":"Drug interactions due to cytochrome P450","volume":"13","author":"Ogu","year":"2000","journal-title":"Proc. (Bayl. Univ. Med. Cent.)"},{"issue":"7","key":"10.1016\/j.bcp.2017.03.019_b0625","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ctrv.2012.12.008","article-title":"Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients","volume":"39","author":"Goey","year":"2013","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2017.03.019_b0630","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/pr.115.011411","article-title":"Role of cytochrome P450 2C8 in drug metabolism and interactions","volume":"68","author":"Backman","year":"2016","journal-title":"Pharmacol. Rev."},{"issue":"5","key":"10.1016\/j.bcp.2017.03.019_b0635","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.apsb.2016.07.016","article-title":"Insights into CYP2B6-mediated drug-drug interactions","volume":"6","author":"Hedrich","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.bcp.2017.03.019_b0640","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2165\/00003088-200039040-00002","article-title":"Pharmacokinetics of artemisinin-type compounds","volume":"39","author":"Navaratnam","year":"2000","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.bcp.2017.03.019_b0645","first-page":"313","article-title":"Metabolism of beta-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450","volume":"26","author":"Grace","year":"1998","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.bcp.2017.03.019_b0650","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1046\/j.1365-2125.1999.00044.x","article-title":"Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin","volume":"48","author":"Svensson","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2017.03.019_b0655","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1472-8206.1999.tb00379.x","article-title":"Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19","volume":"13","author":"Mihara","year":"1999","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2017.03.019_b0660","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0009-9236(03)00092-4","article-title":"Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9","volume":"74","author":"Simonsson","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2017.03.019_b0665","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10928-008-9084-6","article-title":"A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens","volume":"35","author":"Elsherbiny","year":"2008","journal-title":"J. Pharmacokinet Pharmacodyn."},{"issue":"3","key":"10.1016\/j.bcp.2017.03.019_b0670","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000090434","article-title":"Effects of artemisinin, artemether, arteether on the pharmacokinetics of carbamazepine","volume":"76","author":"Sukhija","year":"2006","journal-title":"Pharmacology"},{"issue":"10","key":"10.1016\/j.bcp.2017.03.019_b0675","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00228-005-0037-3","article-title":"Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans","volume":"61","author":"Bapiro","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2017.03.019_b0680","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1472-8206.2007.00471.x","article-title":"Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects","volume":"21","author":"Asimus","year":"2007","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2017.03.019_b0685","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1734-1140(13)71021-1","article-title":"Synergistic anti-cancer activity of the combination of dihydroartemisinin and doxorubicin in breast cancer cells","volume":"65","author":"Wu","year":"2013","journal-title":"Pharmacol. Rep."},{"issue":"5","key":"10.1016\/j.bcp.2017.03.019_b0690","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.3892\/ol.2016.5187","article-title":"In vitro and in vivo inhibition of tumor cell viability by combined dihydroartemisinin and doxorubicin treatment, and the underlying mechanism","volume":"12","author":"Tai","year":"2016","journal-title":"Oncol. Lett."},{"issue":"12","key":"10.1016\/j.bcp.2017.03.019_b0695","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.18632\/oncotarget.1847","article-title":"Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis","volume":"5","author":"Papanikolaou","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2017.03.019_b0700","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.mvr.2013.02.006","article-title":"DHA regulates angiogenesis and improves the efficiency of CDDP for the treatment of lung carcinoma","volume":"87","author":"Zhang","year":"2013","journal-title":"Microvasc. Res."},{"issue":"3","key":"10.1016\/j.bcp.2017.03.019_b0705","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.bbrc.2014.01.053","article-title":"Dihydroartemisinin potentiates the anticancer effect of cisplatin via mTOR inhibition in cisplatin-resistant ovarian cancer cells: involvement of apoptosis and autophagy","volume":"444","author":"Feng","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.bcp.2017.03.019_b0710","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1582-4934.2008.00360.x","article-title":"Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy","volume":"13","author":"Chen","year":"2009","journal-title":"J. Cell Mol. Med."},{"issue":"3","key":"10.1016\/j.bcp.2017.03.019_b0715","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00280-010-1355-4","article-title":"In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents","volume":"67","author":"Gravett","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2017.03.019_b0720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000125673","article-title":"Dihydroartemisinin potentiates the cytotoxic effect of temozolomide in rat C6 glioma cells","volume":"82","author":"Huang","year":"2008","journal-title":"Pharmacology"},{"issue":"2","key":"10.1016\/j.bcp.2017.03.019_b0725","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/18715206113136660340","article-title":"Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines","volume":"14","author":"Karpel-Massler","year":"2014","journal-title":"Anticancer Agents Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2017.03.019_b0730","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3892\/ol.2015.3183","article-title":"Dihydroartemisinin increases temozolomide efficacy in glioma cells by inducing autophagy","volume":"10","author":"Zhang","year":"2015","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bcp.2017.03.019_b0735","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.11972","article-title":"Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence","author":"Berte","year":"2016","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.bcp.2017.03.019_b0740","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1158\/1078-0432.CCR-08-0197","article-title":"Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action","volume":"14","author":"Hou","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2017.03.019_b0745","first-page":"530","article-title":"Experimental study of the function and mechanism combining dihydroartemisinin and gemcitabine in treating pancreatic cancer","volume":"48","author":"Wang","year":"2010","journal-title":"Zhonghua Wai Ke Za Zhi"},{"issue":"1","key":"10.1016\/j.bcp.2017.03.019_b0750","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.canlet.2010.01.001","article-title":"Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo","volume":"293","author":"Wang","year":"2010","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.bcp.2017.03.019_b0755","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s10495-013-0953-0","article-title":"Synergistic induction of apoptosis in A549 cells by dihydroartemisinin and gemcitabine","volume":"19","author":"Zhao","year":"2014","journal-title":"Apoptosis"},{"issue":"9","key":"10.1016\/j.bcp.2017.03.019_b0760","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.bcp.2003.12.035","article-title":"Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774","volume":"67","author":"Efferth","year":"2004","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2017.03.019_b0765","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/ijc.25707","article-title":"The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies","volume":"128","author":"Liu","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2017.03.019_b0770","first-page":"1867","article-title":"Effects of antioxidants and pro-oxidants on cytotoxicity of dihydroartemisinin to Molt-4 human leukemia cells","volume":"35","author":"Gerhardt","year":"2015","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2017.03.019_b0775","first-page":"767","article-title":"The anti-malarial artesunate is also active against cancer","volume":"18","author":"Efferth","year":"2001","journal-title":"Int. J. Oncol."},{"issue":"12","key":"10.1016\/j.bcp.2017.03.019_b0780","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1248\/bpb.25.1555","article-title":"Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562\/adr and GLC4\/adr resistant cell lines","volume":"25","author":"Reungpatthanaphong","year":"2002","journal-title":"Biol. Pharm. Bull."},{"issue":"8","key":"10.1016\/j.bcp.2017.03.019_b0785","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1371\/journal.pone.0000693","article-title":"Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells","volume":"2","author":"Efferth","year":"2007","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.bcp.2017.03.019_b0790","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1021\/ac800231k","article-title":"Same-single-cell analysis for the study of drug efflux modulation of multidrug resistant cells using a microfluidic chip","volume":"80","author":"Li","year":"2008","journal-title":"Anal. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2017.03.019_b0795","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1124\/mol.108.045286","article-title":"Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells","volume":"74","author":"Riganti","year":"2008","journal-title":"Mol. Pharmacol."},{"issue":"7","key":"10.1016\/j.bcp.2017.03.019_b0800","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/j.1476-5381.2009.00117.x","article-title":"Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression","volume":"156","author":"Riganti","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2017.03.019_b0805","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ejmech.2015.10.040","article-title":"Combating P-glycoprotein-mediated multidrug resistance with 10-O-phenyl dihydroartemisinin ethers in MCF-7 cells","volume":"108","author":"Zhong","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"18","key":"10.1016\/j.bcp.2017.03.019_b0810","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.1016\/j.bmc.2012.07.015","article-title":"New artesunic acid homodimers: potent reversal agents of multidrug resistance in leukemia cells","volume":"20","author":"Reiter","year":"2012","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2017.03.019_b0815","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bmcl.2015.11.042","article-title":"Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent","volume":"26","author":"Zhang","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"13","key":"10.1016\/j.bcp.2017.03.019_b0820","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1021\/jm100404t","article-title":"Cytotoxicity of artesunic acid homo- and heterodimer molecules toward sensitive and multidrug-resistant CCRF-CEM leukemia cells","volume":"53","author":"Horwedel","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2017.03.019_b0825","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ejmech.2014.01.043","article-title":"Synthesis and study of cytotoxic activity of 1,2,4-trioxane- and egonol-derived hybrid molecules against Plasmodium falciparum and multidrug-resistant human leukemia cells","volume":"75","author":"Reiter","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2017.03.019_b0830","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejmech.2015.04.053","article-title":"New efficient artemisinin derived agents against human leukemia cells, human cytomegalovirus and Plasmodium falciparum: 2nd generation 1,2,4-trioxane-ferrocene hybrids","volume":"97","author":"Reiter","year":"2015","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2017.03.019_b0835","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1006\/bcmd.2002.0492","article-title":"Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells","volume":"28","author":"Efferth","year":"2002","journal-title":"Blood Cells Mol. Dis."},{"issue":"12","key":"10.1016\/j.bcp.2017.03.019_b0840","doi-asserted-by":"crossref","first-page":"10556","DOI":"10.3390\/molecules161210556","article-title":"The effects of artesunate on the expression of EGFR and ABCG2 in A549 human lung cancer cells and a xenograft model","volume":"16","author":"Ma","year":"2011","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.bcp.2017.03.019_b0845","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3892\/ol.2013.1545","article-title":"Reversal of multidrug resistance by the anti-malaria drug artesunate in the esophageal cancer Eca109\/ABCG2 cell line","volume":"6","author":"Liu","year":"2013","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.bcp.2017.03.019_b0850","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bcp.2009.08.013","article-title":"Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines","volume":"79","author":"Michaelis","year":"2010","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2017.03.019_b0855","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.biopha.2012.10.017","article-title":"Dihydroartemisinin inhibits the Bcr\/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib","volume":"67","author":"Lee","year":"2013","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2017.03.019_b0860","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1748-717X-9-84","article-title":"Artemisinin derivative artesunate induces radiosensitivity in cervical cancer cells in vitro and in vivo","volume":"9","author":"Luo","year":"2014","journal-title":"Radiat. Oncol."},{"issue":"12","key":"10.1016\/j.bcp.2017.03.019_b0865","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s00432-014-1771-7","article-title":"Synergic effects of artemisinin and resveratrol in cancer cells","volume":"140","author":"Li","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1\u20133","key":"10.1016\/j.bcp.2017.03.019_b0870","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejphar.2003.09.057","article-title":"Differential involvement of protein kinase C in human promyelocytic leukemia cell differentiation enhanced by artemisinin","volume":"482","author":"Kim","year":"2003","journal-title":"Eur. J. Pharmacol."},{"issue":"6B","key":"10.1016\/j.bcp.2017.03.019_b0875","first-page":"4325","article-title":"Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells","volume":"25","author":"Singh","year":"2005","journal-title":"Anticancer Res."},{"issue":"10","key":"10.1016\/j.bcp.2017.03.019_b0880","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.7314\/APJCP.2013.14.10.5895","article-title":"Dihydroartemisinine enhances dictamnine-induced apoptosis via a caspase dependent pathway in human lung adenocarcinoma A549 cells","volume":"14","author":"An","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"9","key":"10.1016\/j.bcp.2017.03.019_b0885","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.7314\/APJCP.2013.14.9.5243","article-title":"Synergism of cytotoxicity effects of triptolide and artesunate combination treatment in pancreatic cancer cell lines","volume":"14","author":"Liu","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"8","key":"10.1016\/j.bcp.2017.03.019_b0890","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.7314\/APJCP.2013.14.8.4615","article-title":"The synergistic anticancer effect of artesunate combined with allicin in osteosarcoma cell line in vitro and in vivo","volume":"14","author":"Jiang","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"6","key":"10.1016\/j.bcp.2017.03.019_b0895","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3109\/10428194.2013.829573","article-title":"Artesunate possesses anti-leukemia properties that can be enhanced by arsenic trioxide","volume":"55","author":"Li","year":"2014","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.bcp.2017.03.019_b0900","first-page":"3399","article-title":"Additive cytotoxic effects of dihydroartemisinin and sodium salicylate on cancer cells","volume":"34","author":"Wickerath","year":"2014","journal-title":"Anticancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2017.03.019_b0905","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/iub.1284","article-title":"Artemisinin and curcumin inhibit Drosophila brain tumor, prolong life span, and restore locomotor activity","volume":"66","author":"Das","year":"2014","journal-title":"IUBMB Life"},{"issue":"31","key":"10.1016\/j.bcp.2017.03.019_b0910","doi-asserted-by":"crossref","first-page":"50302","DOI":"10.18632\/oncotarget.10367","article-title":"Halofuginone and artemisinin synergistically arrest cancer cells at the G1\/G0 phase by upregulating p21Cip1 and p27Kip1","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.bcp.2017.03.019_b0915","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/004982599238335","article-title":"Metabolism of artelinic acid to dihydroqinqhaosu by human liver cytochrome P4503A","volume":"29","author":"Grace","year":"1999","journal-title":"Xenobiotica"},{"issue":"5","key":"10.1016\/j.bcp.2017.03.019_b0920","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00003088-200140050-00003","article-title":"Pharmacokinetic interactions of antimalarial agents","volume":"40","author":"Giao","year":"2001","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.bcp.2017.03.019_b0925","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/bdd.342","article-title":"Characterisation of the human liver in vitro metabolic pattern of artemisinin and auto-induction in the rat by use of nonlinear mixed effects modelling","volume":"24","author":"Svensson","year":"2003","journal-title":"Biopharm. Drug Dispos."},{"issue":"5","key":"10.1016\/j.bcp.2017.03.019_b0930","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/bdd.665","article-title":"Artemisinin - a possible CYP2B6 probe substrate?","volume":"30","author":"Asimus","year":"2009","journal-title":"Biopharm. Drug Dispos."},{"issue":"6","key":"10.1016\/j.bcp.2017.03.019_b0935","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1124\/mol.104.009019","article-title":"Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor","volume":"67","author":"Burk","year":"2005","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2017.03.019_b0940","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.vascn.2010.11.002","article-title":"Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2","volume":"63","author":"Rhodes","year":"2011","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"9","key":"10.1016\/j.bcp.2017.03.019_b0945","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1124\/dmd.112.045765","article-title":"Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes","volume":"40","author":"Xing","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2017.03.019_b0950","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/1475-2875-13-214","article-title":"Auto-induction of phase I and phase II metabolism of artemisinin in healthy Chinese subjects after oral administration of a new artemisinin-piperaquine fixed combination","volume":"13","author":"Zang","year":"2014","journal-title":"Malar. J."},{"issue":"1","key":"10.1016\/j.bcp.2017.03.019_b0955","first-page":"30","article-title":"Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s","volume":"29","author":"Bapiro","year":"2001","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.bcp.2017.03.019_b0960","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2174\/1872312811206040004","article-title":"The evaluation of CYP2B6 inhibition by artemisinin antimalarials in recombinant enzymes and human liver microsomes","volume":"6","author":"Ericsson","year":"2012","journal-title":"Drug Metab. Lett."},{"issue":"7","key":"10.1016\/j.bcp.2017.03.019_b0965","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3109\/00498254.2013.878815","article-title":"Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies","volume":"44","author":"Ericsson","year":"2014","journal-title":"Xenobiotica"},{"issue":"5","key":"10.1016\/j.bcp.2017.03.019_b0970","doi-asserted-by":"crossref","first-page":"e96789","DOI":"10.1371\/journal.pone.0096789","article-title":"Evaluation of influence of single nucleotide polymorphisms in cytochrome P450 2B6 on substrate recognition using computational docking and molecular dynamics simulation","volume":"9","author":"Kobayashi","year":"2014","journal-title":"PLoS One"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217301818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217301818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T23:09:17Z","timestamp":1692745757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295217301818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":194,"alternative-id":["S0006295217301818"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2017.03.019","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer combination therapies with artemisinin-type drugs","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2017.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}